A Non-Randomized, Open-Label Clinical Study of Catequentinib Hydrochloride (AL3818) Drug-Drug Interaction (DDI) With Itraconazole and Ticagrelor in Healthy Volunteer Subjects

This is a non-randomized, open-label, fixed-sequence drug-drug interaction study to evaluate the effects of itraconazole and ticagrelor on the pharmacokinetics of catequentinib hydrochloride (AL3818) in healthy volunteers.

Start Date02 Mar 2026

Sponsor / Collaborator

Advenchen Laboratories Nanjing Ltd.

ChiCTR2600116664

/ Not yet recruitingPhase 4IIT

The Efficacy of Tapentadol versus Sufentanil in Preventing Postoperative Nausea and Vomiting after Gynecological Laparoscopic Surgery:A Randomized, Double-Blind, Controlled Trial

Start Date10 Feb 2026

Sponsor / Collaborator-

IRCT20240804062647N11

/ RecruitingNot Applicable

Bioequivalence study of ticagrelor 90 mg tablets - Actovecor Company

Start Date06 Dec 2025

Sponsor / Collaborator-

100 Clinical Results associated with Ticagrelor

100 Translational Medicine associated with Ticagrelor

100 Patents (Medical) associated with Ticagrelor

4,388

Literatures (Medical) associated with Ticagrelor

31 Dec 2026·ANNALS OF MEDICINE

Drug repurposing of ticagrelor suppresses renal cell carcinoma growth by blockading the EGFR/PI3K/AKT axis

Article

Author: Fang, Haihong ; Guo, Yongmei ; Yang, Yuxiu ; Liu, Tongqi ; Zhang, Lin ; He, Yuanqiao ; Zhou, Ting

BACKGROUND:

Renal cell carcinoma (RCC) remains one of the most prevalent urological malignancies. Although targeted therapies have expanded therapeutic options, a substantial proportion of patients still experience poor outcomes, underscoring the need for more effective and less toxic strategies. Ticagrelor, a novel antiplatelet agent, has recently shown antineoplastic potential in several cancers; however, its role and mechanism in RCC remain undefined.

METHODS:

In vitro effects of ticagrelor on RCC cells were evaluated using CCK-8, EdU, and AO/PI assays for proliferation/apoptosis, wound healing and Transwell assays for migration/invasion. In vivo efficacy was assessed in an RCC cell-derived xenograft (CDX) model. Network pharmacology and Western blotting were employed to elucidate the underlying mechanism.

RESULTS:

Ticagrelor suppressed proliferation, migration, invasion and adhesion, and promoted apoptosis in RCC cells. In CDX mice, tumor growth was significantly inhibited. Mechanistically, the EGFR/PI3K/AKT pathway was identified as the key mediator of ticagrelor's antitumor activity in RCC.

CONCLUSIONS:

Ticagrelor exerts anti-RCC effects via blockade of the EGFR/PI3K/AKT signaling axis, highlighting its translational potential and positioning this pathway as a therapeutic target and possible biomarker in RCC.

01 Jul 2026·HEART & LUNG

Risk of acute myocardial infarction with ticagrelor, prasugrel, and clopidogrel prescription after coronary stent restenosis: A retrospective real-world comparative risk analysis with TriNetX

Article

Author: Shah, Atman K ; Lin, Chien-Jung ; Mootz, Nicholas ; Peddada, Venkata Praneeth ; Lu, Ching-Hsien ; Dhruva, Yesh V ; Kumar, Akhil V ; Ponnada, Rohit B

BACKGROUND:

Coronary stent restenosis remains a clinically significant challenge, often resulting in recurrent myocardial infarction (MI). Optimal antiplatelet therapy following restenosis is unclear, as most comparative studies were conducted in broader acute coronary syndrome populations.

METHODS:

We conducted a retrospective cohort study using TriNetX to identify patients with in-stent restenosis (ICD-10: T82.855) who were subsequently prescribed clopidogrel, prasugrel, or ticagrelor. The primary outcome was acute MI (ICD-10: I21) within one year of prescription. Adjusted Cox proportional hazards models compared MI risk between agents, controlling for age, sex, HbA1c, heart failure, CKD, cerebrovascular disease, and mortality.

RESULTS:

Among 40,206 patients, MI occurred in 22.5% of prasugrel users (n=1,139), 29.0% of clopidogrel users (n=35,071), and 35.9% of ticagrelor users (n=4,041). Compared to clopidogrel, ticagrelor was associated with significantly increased MI risk (HR 1.552; 95% CI: 1.467-1.642; p<0.001), while prasugrel showed no significant difference (HR 0.94; 95% CI: 0.835-1.057; p=0.3). Prasugrel was associated with significantly lower risk compared to ticagrelor (HR 0.589; 95% CI: 0.519-0.669; p<0.001).

CONCLUSIONS:

In this real-world cohort of patients with coronary stent restenosis, ticagrelor was associated with a significantly higher 1-year MI risk compared to clopidogrel and prasugrel. These findings suggest potential differences in clinical outcomes among P2Y12 inhibitors in this high-risk setting and highlight the need for further prospective investigation to confirm these results.

01 May 2026·JOURNAL OF MOLECULAR GRAPHICS & MODELLING

Repurposing drugs for EGFR-targeted cancer therapy: An in silico and in vitro study with pharmacophore-based insights

Article

Author: Siyah, Pınar ; Barlas, Firat Baris

Cancer is the second leading cause of death globally and remains a priority due to its impact on life quality, treatment complexity, and high costs. To expedite drug development, researchers are increasingly repurposing FDA-approved drugs and clinical candidates, reducing time and costs through in silico methods. In this study, 3235 FDA-approved and clinical molecules were screened for EGFR inhibition, a significant target due to its role in cancer progression and treatment resistance. A pharmacophore model was generated based on erlotinib's co-crystallized structure and quantitative structure-activity relationships. Molecules meeting the pharmacophoric criteria underwent SP and XP docking, with thresholds of -6.00 kcal/mol and -7.00 kcal/mol, respectively, followed by anti-cancer potential analysis via MetaCore/MetaDrug and MD simulations at 1, 10, and 100 ns to assess EGFR-binding stability. For the molecule Ticagrelor, which demonstrated particularly promising results, and Erlotinib cell culture viability assays were conducted across three cell lines-cancerous A549, U87, and healthy BEAS-2B- (IC50) of, 8.2576 μM, 9.4058 μM, and 15.893 μM, respectively for Ticagrelor and 11.708 μM, 12.747 μM and 14.6709 μM, respectively for Erlotinib. In silico results highlight Ticagrelor's significant EGFR-inhibiting potential with enhanced binding stability compared to the reference.

131

News (Medical) associated with Ticagrelor

19 Mar 2026

·www.prnewswire.com

CytoSorbents Announces HotSwap™ Launch, Renewed Aferetica Partnership, and New Clinical Evidence at ISICEM 2026

PRINCETON, N.J., March 19, 2026 /PRNewswire/ -- CytoSorbents Corporation (NASDAQ: CTSO), a leader in the treatment of life-threatening conditions in the intensive care unit and cardiac surgery using blood purification, today announced three major developments at the International Symposium on Intensive Care and Emergency Medicine (ISICEM) this week in Brussels, Belgium - one of the largest global conferences dedicated to critical care medicine: The introduction of HotSwap™ by CytoSorbents – The New CytoSorb exchange system The renewal of its long-standing partnership with Aferetica Srl in Italy, and New clinical data reinforcing the growing body of evidence supporting CytoSorb® therapy CytoSorbents Launches HotSwap™ to Simplify and Optimize Therapy CytoSorbents announced the immediate availability of HotSwap™, an innovative solution designed to enable rapid, seamless exchange of CytoSorb adsorbers during the treatment of critically-ill patients. HotSwap™ is designed to: Enable faster, easier device exchanges – particularly in high-acuity patients requiring frequent changes Facilitate the safe return of blood from used devices back to the patient Streamline workflows for ICU staff, reducing nursing burden and improving treatment consistency "In critically ill patients, timing, dosing, and treatment intensity are essential to improving outcomes," stated Dr. Phillip Chan, Chief Executive Officer of CytoSorbents. "HotS clinicians to more easily and efficiently treat the right patient, at the right time, with the right dose. Early user feedback has been highly positive, reinforcing our decision to make this technology broadly available." Dr. Chan added, "In life-threatening diseases such as sepsis, acute respiratory distress syndrome, liver failure, and trauma, unstable patients often require multiple device changes per day in the early phase of treatment to control deadly massive inflammation or to reduce high concentrations of toxic substances that can otherwise lead to organ failure and death. HotS this process faster, safer, and more practical, while preserving valuable blood volume and reducing the workload on ICU teams." CytoSorbents Renews Strategic Partnership with Aferetica CytoSorbents also announced the renewal of its exclusive distribution agreement with Aferetica Srl in Italy, extending a successful collaboration spanning more than a decade. The partnership has supported widespread adoption of CytoSorb across critical care and cardiac surgery in Italy. The companies have also collaborated on Aferetica's innovative PerLife® organ perfusion platform, which integrates CytoSorbents' PerSorb® cartridge to improve organ preservation and rehabilitation for transplantation. "Aferetica has been an exceptional long-term partner," stated Dr. Chan. "CEO Mauro Atti and his team, working closely with leading clinicians and researchers in the country, have played a critical role in advancing both the clinical adoption and scientific understanding of CytoSorb therapy. We are excited to continue working together to expand innovation in blood purification and organ transplantation." Mr. Mauro Atti, Chief Executive Officer of Aferetica SRL stated, "We are happy to continue our successful collaboration with CytoSorbents that has contributed to the growth of our companies and importantly, the care and recovery of many patients. For more than ten years, we have shared the vision that blood purification can significantly improve outcomes in critically ill patients. Together we have successfully expanded from sepsis into liver failure and other critical illnesses, and now organ transplantation. We look forward to many more years of continued progress and shared success." New Clinical Data and Scientific Leadership at ISICEM 2026 Today, CytoSorbents is hosting a featured symposium at ISICEM entitled: "Hemoadsorption as part of an individualized patient concept in Intensive Care – Key Learnings and Best Practices" Chair: Dr. Ricard Ferrer, Barcelona/Spain and Dr. Zsolt Molnar, Budapest/Hungary The importance of timing and dosing in different indications Dr. Gerd Klinkmann, Rostock/Germany Update on drug removal – we are on the safe side if we do it right Dr. Gabriella Bottari, Rome/Italy The new kid on the block – Cytokine Release Syndrome (CRS) after CAR-T cell therapy Dr. Peter Pickkers, Nijmegen/The Netherlands In addition, multiple abstracts and poster presentations presented at ISICEM further strengthen the clinical evidence base for CytoSorb therapy (click on title for full abstract): COSMOS Registry – Real-World Critical Care Outcomes (n=306, 23 sites, 6 countries) Significant reductions in vasopressor requirements, improved oxygenation, and fluid balance (all p<0.0001) ICU mortality of 32.7%, lower than predicted by severity scores 90-day survival of 56.5%, with >90% dialysis independence Rhabdomyolysis Substudy (n=45) Significant reduction in myoglobin levels (~8,800 → ~3,000 µg/L, p<0.0001) Improved kidney function markers 71% ICU survival; only 8% dialysis-dependent at 90 days Toxic Shock Syndrome Case Series (n=7) Rapid improvements in SOFA scores, lactate, and inflammatory biomarkers Shock reversal in 6 of 7 patients; 6 survivors to ICU discharge In Vitro Comparative Study CytoSorb demonstrated the strongest reduction of inflammatory cytokines versus competing hemoperfusion systems Competing systems showed limited efficacy or unfavorable inflammatory responses Meta-Analysis in COVID-19 (n=875) Trend toward reduced mortality (OR 0.74) No evidence of harm, supporting continued use in hyperinflammatory conditions "These data and clinical experiences continue to reinforce CytoSorb's role as a versatile, frontline blood purification therapy across a broad range of critical illnesses," added Dr. Chan. "Together with innovations like HotSwap™, we are making it easier for clinicians to deliver consistent, high-quality care to the sickest patients." About CytoSorbents Corporation (NASDAQ: CTSO) CytoSorbents Corporation is a leader in the treatment of life-threatening conditions in the intensive care unit and cardiac surgery through blood purification. CytoSorbents' proprietary blood purification technologies are based on biocompatible, highly porous polymer beads that can actively remove toxic substances from blood and other bodily fluids by pore capture and surface adsorption. Cartridges filled with these beads can be used with standard blood pumps already in the hospital (e.g. dialysis, continuous renal replacement therapy or CRRT, extracorporeal membrane oxygenation or ECMO, and heart-lung machines), where blood is repeatedly recirculated outside the body, through our cartridges where toxic substances are removed, and then back into the body. CytoSorbents' technologies are used in a number of broad applications. Specifically, two important applications are 1) the removal of blood thinners during and after cardiothoracic surgery to reduce the risk of severe bleeding, and 2) the removal of inflammatory agents and toxins in common critical illnesses that can lead to massive inflammation, organ failure and patient death. The breadth of these critical illnesses includes, for example, sepsis, burn injury, trauma, lung injury, liver failure, cytokine storm and cytokine release syndrome, and pancreatitis as well as the removal of liver toxins that accumulate in acute liver dysfunction or failure, and the removal of myoglobin in severe rhabdomyolysis that can otherwise lead to renal failure. In these diseases, the risk of death can be extremely high, and there are few, if any, effective treatments. CytoSorbents' lead product, CytoSorb ®, is approved in the European Union and distributed in over 70 countries worldwide, with more than 300,000 devices used cumulatively to date. CytoSorb® was originally launched in the European Union under CE mark as the first cytokine adsorber. Additional CE mark extensions were granted for bilirubin and myoglobin removal in clinical conditions such as liver disease and trauma, respectively, and for ticagrelor and rivaroxaban removal in cardiothoracic surgery procedures. CytoSorb® has also received FDA Emergency Use Authorization in the United States for use in adult critically ill COVID-19 patients with impending or confirmed respiratory failure. CytoSorb® is not yet approved or cleared in the United States. In the U.S. and Canada, CytoSorbents is developing the DrugSorb®-ATR antithrombotic removal system, an investigational device based on an equivalent polymer technology to CytoSorb®, to reduce the severity of perioperative bleeding in high-risk surgery due to blood thinning drugs. It has received two FDA Breakthrough Device Designations: one for the removal of ticagrelor and another for the removal of the direct oral anticoagulants (DOAC) apixaban and rivaroxaban in a cardiopulmonary bypass circuit during urgent cardiothoracic surgery. The Company is actively pursuing regulatory approval of DrugSorb®-ATR with the U.S. FDA and will pursue regulatory approval with Health Canada with better visibility from the FDA. DrugSorb®-ATR is not yet granted or approved in either the U.S. or Canada. The Company has numerous marketed products and products under development based upon this unique blood purification technology protected by many issued U.S. and international patents and registered trademarks, and multiple patent applications pending, including ECOS-300CY®, VetResQ®, Purifi®, HotSwap™, CytoSorb-XL™, HemoDefend-RBC™, HemoDefend-BGA™, K+ontrol™, DrugSorb®, ContrastSorb, and others. For more information, please visit the Company's website at and follow us on Facebook and X and LinkedIn. Forward-Looking Statements This press release includes forward-looking statements intended to qualify for the safe harbor from liability established by the Private Securities Litigation Reform Act of 1995. These forward-looking statements include, but are not limited to, statements about our plans, objectives, future targets and outlooks for our business, representations and contentions, and the outcome of our regulatory submissions, and are not historical facts and typically are identified by use of terms such as "may," "should," "could," "expect," "plan," "anticipate," "believe," "estimate," "predict," "potential," "continue" and similar words, although some forward-looking statements are expressed differently. You should be aware that the forward-looking statements in this press release represent management's current judgment and expectations, but our actual results, events and performance could differ materially from those in the forward-looking statements. Factors which could cause or contribute to such differences include, but are not limited to, our restructuring of our direct sales team and strategy in Germany, ability to successfully obtain U.S. FDA and Health Canada marketing authorization or approval, our ability to complete our strategic workforce and cost reduction plan to reduce costs, optimize operations, and achieve cash-flow break-even in the first quarter of 2026, our ability to appropriately finance the Company, and the risks discussed in our Annual Report on Form 10-K, filed with the SEC on March 31, 2025, as updated by the risks reported in our Quarterly Reports on Form 10-Q, and in the press releases and other communications to shareholders issued by us from time to time which attempt to advise interested parties of the risks and factors which may affect our business. We caution you not to place undue reliance upon any such forward-looking statements. We undertake no obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events, or otherwise, other than as required under the Federal securities laws. Please Click to Follow Us on Facebook and X U.S. Company Contact: Peter J. Mariani, Chief Financial Officer [email protected] Investor Relations Contacts: Aman Patel, CFA & Adanna G. Alexander, PhD ICR Healthcare [email protected] SOURCE Cytosorbents Corp 21% more press release views with Request a Demo

Drug Approval

11 Feb 2026

·firstwordpharma.com

Biopharma bites: Another FDA nod for Keytruda, oveporexton's PDUFA...and more

Keytruda racks up another approval, this time in ovarian cancersFDA will rule on oveporexton in the third-quarterBiocodex picks up two rare disease programmes from THX PharmaRivaroxaban combo axed from major US stroke trialKeytruda racks up another approval, this time in ovarian cancersThe FDA on Tuesday approved both the infused and subcutaneous formulations of Merck & Co.'s Keytruda (pembrolizumab) in combination with chemotherapy, with or without bevacizumab, to treat adults with platinum-resistant epithelial ovarian, fallopian tube, or primary peritoneal carcinoma whose tumours express PD-L1 and who have received one or two prior systemic treatment regimens. While the PD-1 inhibitor brought in more than $30 billion in sales last year, it's rapidly approaching a 2028 patent expiration (see – Spotlight On: Merck & Co.'s fastest selling drugs in 2025).The approval was based on findings from the Phase III KEYNOTE-B96 trial, the first time an immunotherapy-based regimen has shown such a broad benefit in the specific patient population. In patients with PD-L1–positive tumours, the Keytruda regimen led to median progression-free survival of 8.3 months and median overall survival of 18.2 months; the placebo arm saw a benefit of 7.2 months and 14 months, respectively. Alongside Keytruda's approval, the FDA cleared the PD-L1 IHC 22C3 pharmDx test from Agilent Technologies as a companion diagnostic to identify patients with epithelial ovarian, fallopian tube, or primary peritoneal carcinoma whose tumours express PD-L1 and may be eligible for treatment.-Elizabeth EatonFDA will rule on oveporexton in the third-quarterAn application for Takeda's oral narcolepsy candidate was granted priority review on Tuesday, with a PDUFA date penciled in for the third quarter. Oveporexton (TAK-861) stands to become the first orexin agonist approved for narcolepsy type 1 (NT1) (see – ViewPoints: With oveporexton at the helm, Takeda’s orexin push gains steam).In July, the Japanese pharma reported that oveporexton met all primary and secondary goals in a pair of Phase IIl NT1 trials, and at the World Sleep conference in September shared detailed results showing that the majority of participants treated with a 2-mg dose achieved "normal" wakefulness (see – Spotlight On: Narcolepsy win provides more pipeline momentum for Takeda).The data were well received by physicians. A FirstWord survey fielded to neurologists found that more than half are very likely to prescribe oveporexton if it is approved (see – Physician Views Results: Strong prescriber interest suggests oveporexton could awaken orexin’s long-awaited potential)And that approval is looking likely. An expert told FirstWord that there is "no way" that regulators could refuse oveporexton because it "is the first drug that seems to work on all the symptoms and right from the start, and can completely change the life of a patient." For further feedback, see KOL Views Q&A: Takeda’s oveporexton is raising the bar for narcolepsy drugs, rival orexin agonists.-Elizabeth EatonBiocodex picks up two rare disease programmes from THX Pharma Biocodex padded its pipeline on Tuesday, thanks to a pair of licensing deals with THX Pharma. The drugmaker nabbed exclusive worldwide rights to Batten-1, an experimental treatment for juvenile Batten disease that's slated to enter Phase III testing this year; it's on track for a 2030 international launch.Biocodex also licensed US and Canadian rights for TX01 to treat Gaucher disease and Niemann-Pick type C disease. The programme is an adapted oral formulation of an already approved active substance.THX will receive €12 million ($14.3 million) upfront, and is eligible for up to €161 million ($191.5 million) in development and commercialisation milestone payments, plus double-digit tiered royalties. The company will be responsible for each asset's clinical development, while Biocodex will helm commercialisation activities in its respective territories. -Elizabeth EatonRivaroxaban combo axed from major US stroke trialThe US National Institutes of Health has halted one arm of a large clinical trial evaluating treatments to prevent strokes, after investigators determined that rivaroxaban combined with aspirin was linked to "an increase in safety events" and was unlikely to provide benefit over the current standard.The decision followed a routine review by an independent data safety and monitoring board overseeing the CAPTIVA study.The discontinued arm tested a low dose of the oral anticoagulant — marketed as Xarelto by Johnson & Johnson and Bayer — alongside daily aspirin in patients who had suffered a stroke attributed to stenosis of a major intracranial artery. CAPTIVA is enrolling up to 1683 participants and is designed to determine whether newer blood-thinning regimens outperform the current standard of care, clopidogrel plus aspirin.The study will now proceed by comparing ticagrelor, sold by AstraZeneca as Brilinta, plus aspirin against the clopidogrel-based standard therapy.-Anna Bratulic

Clinical ResultPhase 3Drug ApprovalPhase 2License out/in

10 Feb 2026

·www.fiercepharma.com

NIH stops Xarelto arm of stroke trial due to safety, lack of efficacy

The National Institutes of Health-funded Captiva study found that the combination of a low dose of Xarelto and aspirin was unlikely to help prevent recurrent strokes compared with standard of care in patients with narrowed brain arteries. The National Institutes of Health (NIH) halted a treatment arm of Bayer and Johnson & Johnson’s Xarelto (rivaroxaban) in a phase 3 stroke prevention trial after an independent committee flagged safety concerns and a lack of efficacy.The decision, announced Tuesday, follows a recommendation from a data safety and monitoring board, which found that the combination of a low dose of Xarelto and aspirin was unlikely to help prevent recurrent strokes compared with the standard of care in the phase 3 Captiva study.The board identified “an increase in safety events and evidence of futility,” the NIH—which funded the study—said in a Feb. 10 release. The release didn’t identify the specific safety signals.Xarelto’s current FDA label includes a boxed warning about increased risks of blood clots upon premature discontinuation. Anticoagulants like Xarelto may also cause serious bleeding.In the study, Xarelto was evaluated at a dose of 2.5 mg twice daily and was compared against clopidogrel (Plavix), both on top of aspirin. The trial has a second experimental arm evaluating AstraZeneca’s Brilinta and aspirin.The goal of the trial is to see whether either of the two blood-thinning regimens would be better than the current treatment to prevent another stroke in patients with narrowed brain arteries, which is one of the most common causes of stroke worldwide. The study is evaluating up to 1,683 participants, who are randomized 1:1:1 to receive one year of treatment with one of those three aspirin combo regimens.In a statement to Fierce Pharma, a J&J spokesperson said the discontinuation is “not related to any approved indications for Xarelto.” First approved by the FDA in 2011, Xarelto’s U.S. label includes its uses at 15 mg or 20 mg once daily to reduce the risk of stroke and systemic embolism in nonvalvular atrial fibrillation. The regimen utilized in the Captiva study—2.5 mg Xarelto twice daily, in combination with aspirin—is approved by the FDA to reduce the risk of certain cardiovascular events, including stroke, in people with chronic coronary artery disease or peripheral artery disease.Generic versions of Xarelto are already available in the U.S. after Lupin and Taro Pharmaceuticals gained the first FDA approvals for their 2.5 mg copycats last year and launched immediately. Last year, Xarelto’s U.S. sales to J&J reached $2.6 billion, marking 11% growth compared with 2024. That said, the drug's fourth-quarter sales were roughly flat year over year.As Xarelto ages, J&J is shifting its focus to Bristol Myers Squibb-partnered factor XIa inhibitor milvexian, which is expected to report phase 3 results in secondary stroke prevention in the second half of 2026. J&J has predicted the new antithrombotic agent could reach more than $5 billion in peak annual sales. “What we’re really looking to show there is clear superiority in terms of safety and bleeding risk,” Jennifer Taubert, who leads J&J’s pharmaceuticals business, said about milvexian during the company’s fourth-quarter earnings call in January.“We know from all of our experience in the market with Xarelto that there are a lot of patients that are not treated or are undertreated because of fear of safety risk,” she continued. “So we think there’s extraordinary need for a highly efficacious and highly safe with low bleeding risk product in the market.”Editor's Note: The story was updated at 7:45 p.m. U.S. ET with a statement from J&J.

Phase 3Drug ApprovalClinical Result

100 Deals associated with Ticagrelor

External Link

KEGG	Wiki	ATC	Drug Bank
D09017	Ticagrelor	B01AC24	DB08816

R&D Status

Approved

10 top approved records.

to view more data

Indication	Country/Location	Organization	Date
Acute Ischemic Stroke	United States	AstraZeneca Pharmaceuticals LP	05 Nov 2020
Ischemic Attack, Transient	United States	AstraZeneca Pharmaceuticals LP	05 Nov 2020
Coronary Artery Disease	United States	AstraZeneca Pharmaceuticals LP	28 May 2020
Myocardial Infarction	Japan	AstraZeneca KK	28 Sep 2016
Angina, Unstable	Australia	AstraZeneca Pty Ltd.	21 Jun 2011
Non-St Elevated Myocardial Infarction	Australia	AstraZeneca Pty Ltd.	21 Jun 2011
ST Elevation Myocardial Infarction	Australia	AstraZeneca Pty Ltd.	21 Jun 2011
Acute Coronary Syndrome	European Union	AstraZeneca AB	03 Dec 2010
Acute Coronary Syndrome	Iceland	AstraZeneca AB	03 Dec 2010
Acute Coronary Syndrome	Liechtenstein	AstraZeneca AB	03 Dec 2010
Acute Coronary Syndrome	Norway	AstraZeneca AB	03 Dec 2010
Atherosclerosis	European Union	AstraZeneca AB	03 Dec 2010
Atherosclerosis	Iceland	AstraZeneca AB	03 Dec 2010
Atherosclerosis	Liechtenstein	AstraZeneca AB	03 Dec 2010
Atherosclerosis	Norway	AstraZeneca AB	03 Dec 2010

Developing

10 top R&D records.

to view more data

Indication	Highest Phase	Country/Location	Organization	Date
Acute Chest Syndrome	Phase 3	-	AstraZeneca PLC	30 Jun 2020
Diabetes Mellitus	Phase 3	-	AstraZeneca PLC	15 Sep 2019
Microvascular Disease	Phase 3	-	AstraZeneca PLC	15 Sep 2019
Anemia, Sickle Cell	Phase 3	United States	AstraZeneca PLC	26 Sep 2018
Anemia, Sickle Cell	Phase 3	Belgium	AstraZeneca PLC	26 Sep 2018
Anemia, Sickle Cell	Phase 3	Brazil	AstraZeneca PLC	26 Sep 2018
Anemia, Sickle Cell	Phase 3	Egypt	AstraZeneca PLC	26 Sep 2018
Anemia, Sickle Cell	Phase 3	Ghana	AstraZeneca PLC	26 Sep 2018
Anemia, Sickle Cell	Phase 3	Greece	AstraZeneca PLC	26 Sep 2018
Anemia, Sickle Cell	Phase 3	India	AstraZeneca PLC	26 Sep 2018

Clinical Result

Indication

Phase

Evaluation

View All Results

Study	Phase	Population	Analyzed Enrollment	Group	Results	Evaluation	Publication Date


NCT03476369 (FACTPCI, CTgov)	Phase 4	-	45	Fentanyl+Ticagrelor 90Mg Tablet (Fentanyl and Crushed Ticagrelor)	zkjiplpixy(lkyjykbljp) = vujqypvtgr hzftcruami (vmykzdyaod, ceohojtdxg - hzrrlnnylt) View more	-	04 Feb 2026
				Fentanyl+Ticagrelor 90Mg Tablet (Fentanyl and Non-crushed Ticagrelor)	zkjiplpixy(lkyjykbljp) = zhiecoxjph hzftcruami (vmykzdyaod, pevpjwqchz - gnzsfwlylh) View more
NCT02494895 \| NCT03797651 (T-PASS, Pubmed \| EuroIntervention)	Phase 4	Acute Coronary Syndrome	2,248	Ticagrelor (Discontinuation within 1 month)	iuqyenheqg(bhxzcshvjd) = qvaulwclpe gjuskuwbqw (xzbkpyxjhc ) View more	Positive	01 Feb 2026
				Ticagrelor (Discontinuation at 3 months)	iuqyenheqg(bhxzcshvjd) = xerzclgfag gjuskuwbqw (xzbkpyxjhc ) View more
NCT04078737 (CHANCE-2, Pubmed \| CMAJ)	Phase 3	Stroke \| Ischemic Attack, Transient CYP2C19 loss-of-function mutations	4,954	Ticagrelor-acetylsalicylic acid (low-insulin resistance group)	dejlwnwzak(exvbzpxrud) = dfbnhbhptz jbncmuylja (lemaplwusv )	Positive	19 Jan 2026
				Clopidogrel-ASA (low-insulin resistance group)	dejlwnwzak(exvbzpxrud) = pmeuqmqkox jbncmuylja (lemaplwusv )
NCT04078737 (CHANCE-2, Pubmed \| J Am Heart Assoc)	Phase 3	Ischemic Attack, Transient \| Ischemic stroke	5,651	Aspirin-Ticagrelor	vqhrkctgyk(iengnkrbze) = qnsrskdtxy ssjfnkfkfi (kkiynvwoeg ) View more	Positive	18 Dec 2025
				Clopidogrel-Aspirin	vqhrkctgyk(iengnkrbze) = blcpixzluj ssjfnkfkfi (kkiynvwoeg ) View more
NCT03560310 (TACSI, Pubmed \| N Engl J Med)	Phase 3	Acute Coronary Syndrome	2,201	Ticagrelor plus aspirin	ncorxozqjl(amflrvxrnf) = wtfdixadrw zjopdmnhek (nyktdmkrqm ) View more	Negative	11 Dec 2025
				Aspirin alone	ncorxozqjl(amflrvxrnf) = lowhanhfcc zjopdmnhek (nyktdmkrqm ) View more
NCT06318481 (TADCLOT, Pubmed \| J Am Coll Cardiol)	Phase 4	ST Elevation Myocardial Infarction	2,201	Ticagrelor (180 mg loading dose, 90 mg BID)	xxfcjsifxq(jpwwudvlys) = pqtchvqiex lbdyuzwnut (bnhltkfbjw ) View more	Negative	01 Dec 2025
				Clopidogrel (600 mg loading dose, 75 mg BID)	xxfcjsifxq(jpwwudvlys) = dmsoespmzy lbdyuzwnut (bnhltkfbjw ) View more
NCT03465644 (TAILORED-CHIP, Pubmed \| Eur Heart J)	Phase 4	-	2,018	Tailored antiplatelet strategy with early escalation and late de-escalation	qprkstzbnh(grpmycnwdc) = ezcafvjbis hjgwgsmeaz (kxcupymfqa ) View more	Negative	31 Aug 2025
				Dual antiplatelet therapy	qprkstzbnh(grpmycnwdc) = hgqvwdnmcm hjgwgsmeaz (kxcupymfqa ) View more
NCT04483583 (SWAP-AC-2, CTgov)	Phase 4	Coronary Artery Disease	81	Clopidogrel (ABCD-GENE >10 - Clopidogrel)	qyafoiubyw(hwvtkmobgm) = ydleschdhl ptktdlsfqd (lbpvmycyuu, srxfwuxzih - qglrnqvqvr) View more	-	31 Jul 2025
				Ticagrelor 60mg (ABCD-GENE >10 - Ticagrelor)	qyafoiubyw(hwvtkmobgm) = imuurcuxip ptktdlsfqd (lbpvmycyuu, rroytnzfxn - rmbydrpnua) View more
NCT02733341 (CTgov)	Phase 4	Acute Coronary Syndrome \| Angina, Unstable \| ST Elevation Myocardial Infarction ... View more	100	Ticagrelor (Oral Ticagrelor)	uaypwhxlhm(kpnpdjfsau) = hzatqlxjnj osoozaotpd (tunkekxwrz, 55.1) View more	-	02 May 2025
				Cangrelor (Intravenous Cangrelor)	uaypwhxlhm(kpnpdjfsau) = ycwrtrbquy osoozaotpd (tunkekxwrz, 50.6) View more
NCT04484259 (OPTIMUS-7, CTgov)	Phase 4	Diabetes Mellitus, Type 2 \| Coronary Artery Disease	105	Ticagrelor monotherapy (Ticagrelor)	tjjkmcjbyw(oikpcwcopt) = pzxbjpfiip volitjesrz (vfzpoigdaw, ezmmrpathv - tcpoanebis) View more	-	30 Mar 2025
				Clopidogrel+aspirin (Aspirin Plus Clopidogrel)	tjjkmcjbyw(oikpcwcopt) = vagmpsysmn volitjesrz (vfzpoigdaw, vospffucvw - oxeaeabxas) View more

Translational Medicine

Boost your research with our translational medicine data.

view full example data

Deal

Boost your decision using our deal data.

view full example data

Core Patent

Boost your research with our Core Patent data.

view full example data

Clinical Trial

Identify the latest clinical trials across global registries.

view full example data

Approval

Accelerate your research with the latest regulatory approval information.

view full example data

Regulation

Understand key drug designations in just a few clicks with Synapse.

view full example data

AI Agents Built for Biopharma Breakthroughs

Accelerate discovery. Empower decisions. Transform outcomes.

Get started for free today!

Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.

Start your data trial now!

Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.

Bio

Bio Sequences Search & Analysis

Chemical

Chemical Structures Search & Analysis

Ticagrelor

Overview

Basic Info

Structure/Sequence

Related

External Link

R&D Status

Clinical Result

Translational Medicine

Deal

Core Patent

Clinical Trial

Approval

Regulation